Literature DB >> 176436

Characterization of Epstein-Barr virus antigens. I. Biochemical analysis of the complement-fixing soluble antigen and relationship with Epstein-Barr virus-associated nuclear antigen.

G Lenoir, M C Berthelon, M C Favre, G de-Thé.   

Abstract

The Epstein-Barr virus-soluble (S) antigen extracted from RAJI cells was characterized by sucrose gradient centrifugation, gel filtration, and ion-exchange chromatography. The sedimentation coefficient was estimated to be 8.5S corresponding to a molecular weight of 180,000. The S antigen binds to DEAE-A25 ion exchanger from which it can be eluted with 0.3 M NaCl in Tris buffer (pH 7.2). All fractions which contained complement-fixing S antigen also inhibited the anticomplement immunofluorescence reaction as used to detect the Epstein-Barr virus-associated nuclear antigen. These results are consistent with the hypothesis that the S and Epstein-Barr virus-associated nuclear antigens are either a single antigen or that both activities are present on the same molecule.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 176436      PMCID: PMC515457     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  10 in total

1.  Application of a microtechnique to viral serological investigations.

Authors:  J L SEVER
Journal:  J Immunol       Date:  1962-03       Impact factor: 5.422

2.  Nasopharyngeal carcinoma. IX. Antibodies to EBNA and correlation with response to other ebv antigens in chinese patients.

Authors:  G de-Thé; J H Ho; D V Ablashi; N E Day; A J Macario; M C Martin-Berthelon; G Pearson; R Sohier
Journal:  Int J Cancer       Date:  1975-11-15       Impact factor: 7.396

3.  Proteins specified by herpes simplex virus. XI. Identification and relative molar rates of synthesis of structural and nonstructural herpes virus polypeptides in the infected cell.

Authors:  R W Honess; B Roizman
Journal:  J Virol       Date:  1973-12       Impact factor: 5.103

4.  Isolation and characterization of a large molecular-weight polypeptide of herpes simplex virus type 1.

Authors:  R J Courtney; M Benyesh-Melnick
Journal:  Virology       Date:  1974-12       Impact factor: 3.616

5.  Relationship between Epstein-Barr virus-determined complement-fixing antigen and nuclear antigen detected by anticomplement fluorescence.

Authors:  G Klein; V Vonka
Journal:  J Natl Cancer Inst       Date:  1974-12       Impact factor: 13.506

6.  Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies.

Authors:  B M Reedman; G Klein; J H Pope; M K Walters; J Hilgers; S Singh; B Johansson
Journal:  Int J Cancer       Date:  1974-06-15       Impact factor: 7.396

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  Significance of a complement-fixing antigen associated with herpes-like virus and detected in the Raji cell line.

Authors:  J H Pope; M K Horne; E J Wetters
Journal:  Nature       Date:  1969-04-12       Impact factor: 49.962

9.  Epstein-Barr virus-induced viral and soluble complement-fixing antigens in Burkitt lymphoma cell cultures.

Authors:  P Gerber; D R Deal
Journal:  Proc Soc Exp Biol Med       Date:  1970-07

10.  Lymphoblastoid transformation and kinetics of appearance of viral nuclear antigen (EBNA) in cord-blood lymphocytes infected by Epstein-Barr Virus (EBV).

Authors:  J Yata; C Desgranges; T Nakagawa; M C Favre; G De-The
Journal:  Int J Cancer       Date:  1975-03-15       Impact factor: 7.396

  10 in total
  11 in total

1.  No activation of new initiation points for deoxyribonucleic acid replication in BALB/c 3T3 cells transformed by Kirsten sarcoma virus.

Authors:  A Oppenheim; A T Horowitz
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

2.  Solubilization of the Epstein-Barr virus-determined nuclear antigen and its characterization as a DNA-binding protein.

Authors:  J Luka; W Siegert; G Klein
Journal:  J Virol       Date:  1977-04       Impact factor: 5.103

3.  Epstein-barr virus-specific RNA. II. Analysis of polyadenylated viral RNA in restringent, abortive, and prooductive infections.

Authors:  T Orellana; E Kieff
Journal:  J Virol       Date:  1977-05       Impact factor: 5.103

4.  Initiation points for cellular deoxyribonucleic acid replication in human lymphoid cells converted by Epstein-Barr virus.

Authors:  A Oppenheim; Z Shlomai; H Ben-Bassat
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

5.  Purification of the Epstein-Barr virus-determined nuclear antigen from Epstein-Barr virus-transformed human lymphoid cell lines.

Authors:  J Luka; T Lindahl; G Klein
Journal:  J Virol       Date:  1978-09       Impact factor: 5.103

6.  Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000-dalton subunit.

Authors:  J Luka; H Jörnvall; G Klein
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

7.  Evidence for two classes of chromatin-associated Epstein-Barr virus-determined nuclear antigen.

Authors:  T C Spelsberg; T B Sculley; G M Pikler; J A Gilbert; G R Pearson
Journal:  J Virol       Date:  1982-08       Impact factor: 5.103

8.  Induction of Epstein-Barr virus nuclear antigen and DNA synthesis in a human epithelial cell line after Epstein-Barr virus infection.

Authors:  H Ben-Bassat; S Mitrani-Rosenbaum; N Goldblum
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

9.  One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.

Authors:  K Hennessy; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205

10.  Antibodies to the Epstein-Barr virus nuclear antigen and to rheumatoid arthritis nuclear antigen identify the same polypeptide.

Authors:  P B Billings; S O Hoch; P J White; D A Carson; J H Vaughan
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.